Cation News and Research

RSS

Antibacterial activity of clay minerals raises hope for natural approaches to antibacterial cures

Alternative approaches to medicine are stock-in-trade in the ASU laboratory of microbiologist Shelley Haydel.

6 Mar 2010

Health Canada approves Talecris Biotherapeutics' PROLASTIN-C for AAT deficiency

Talecris Biotherapeutics announced today that it has received approval from Health Canada for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), a more purified and concentrated version of PROLASTIN® produced using advances in manufacturing technology. A similar approval for PROLASTIN-C was granted by the U.S. Food and Drug Administration on October 17, 2009.

17 Feb 2010

Talecris Biotherapeutics' PROLASTIN-C receives FDA approval

Talecris Biotherapeutics (Nasdaq: TLCR) today received approval from the U.S. Food and Drug Administration for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), a more concentrated version of PROLASTIN® produced using advances in manufacturing technology.

19 Oct 2009

oct3 protein key to Parkinson's, drug addiction

Scientists have identified a protein that appears not only to be central to the process that causes Parkinson's disease but could also play a role in muting the high from methamphetamine and other addictive drugs.

4 May 2009

Tiny genetic change keeps nicotine from binding to muscle cells

A tiny genetic mutation is the key to understanding why nicotine--which binds to brain receptors with such addictive potency--is virtually powerless in muscle cells that are studded with the same type of receptor.

23 Mar 2009

Tethered bilayer membrane may unlock secrets of early-stage Alzheimer's

Researchers at the National Institute of Standards and Technology (NIST) and three collaborating institutions are using a new laboratory model of the membrane surrounding neurons in the brain to study how a protein long suspected of a role in early-stage Alzheimer's disease actually impairs a neuron's structure and function.

23 Jul 2008